Archive

May 28, 2025

Browsing

Get the latest stock market update with Mary Ellen McGonagle. Learn key downside signals, how to manage pullbacks, and which earnings reports could impact the market next week.

In this week’s episode, Mary Ellen reviews where the markets currently stand and what to watch for to signal further downside. She also highlights ways to combat inevitable pullbacks and shares the key earnings reports that are likely to move the markets in the upcoming week.

This video originally premiered May 23, 2025. You can watch it on our dedicated page for Mary Ellen’s videos.

New videos from Mary Ellen premiere weekly on Fridays. You can view all previously recorded episodes at this link.

If you’re looking for stocks to invest in, be sure to check out the MEM Edge Report! This report gives you detailed information on the top sectors, industries and stocks so you can make informed investment decisions.

Confused by mixed market signals? Follow along as Julius analyzes sector rotation, asset rotation, and global market trends using daily and weekly Relative Rotation Graphs (RRGs).

In this video, Julius puts the current sector rotation in perspective on both weekly and daily Relative Rotation Graphs (RRGs). He also examines asset rotation and the position of the U.S. markets in relation to international equities.

This video was originally published on May 27, 2025. Click on the icon above to view on our dedicated page for Julius.

Past videos from Julius can be found here.

#StayAlert, -Julius

In this video, Chip Anderson, President of StockCharts, sits down with Tony for a conversation in the StockCharts studio! During this in-depth Q&A session, Chip and Tony explore the powerful features that make the OptionsPlay add-on a must-have for options traders using the StockCharts platform. They discuss the integration of the StockCharts Scanning Engine with OptionsPlay strategies—showcasing how this tool enhances your ability to find trade setups quickly and effectively.

This video premiered on May 23, 2025.

In this must-see market update, Larry Williams returns with timely stock market analysis, trading insights, and macroeconomic forecasts. Discover what’s next for the Federal Reserve, interest rates, and inflation — and how it could impact top stocks like Tesla (TSLA), Nvidia (NVDA), Apple (AAPL), and consumer staples (XLP).

This video originally premiered on May 27, 2025. Watch on StockCharts’ dedicated Larry Williams page!

Previously recorded videos from Larry are available at this link.

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills and typically affects people in their mid-60s.

According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.

This condition affects more than 7 million people in the US alone; it’s also the most common form of dementia and is the seventh leading cause of death in America. Treatments are available to alleviate Alzheimer’s disease symptoms, but there are currently none that affect the underlying causes of this neurodegenerative disease.

Alzheimer’s disease therapies that have been approved by the US Food and Drug Administration (FDA) include: rivastigmine by Novartis (NYSE:NVS); galantamine, developed by Janssen, a division of Johnson & Johnson (NYSE:JNJ); donepezil by Pfizer (NYSE:PFE); and memantine by AbbVie (NYSE:ABBV).

Since there is no cure for Alzheimer’s disease, death is often the result for patients as the ailment causes brain deterioration. And unfortunately, Alzheimer’s disease is rising in prevalence — a report from Grand View Research suggests that the global Alzheimer’s disease treatment market will be worth a significant US$15.57 billion by 2030 as more patients need treatment, and as more investments are made in biomarkers for diagnosis and drug development.

1. Biogen (NASDAQ:BIIB)

Market cap: US$18.43 billion
Share price: US$125.81

The first NASDAQ-listed Alzheimer’s drug company on this list is Massachusetts-based Biogen, a pioneer in the field of neuroscience. The firm is focused on developing, manufacturing and marketing therapies aimed at treating serious neurological, neurodegenerative, autoimmune and rare diseases.

The global biotechnology firm’s research areas include Alzheimer’s disease and dementia. However, the launch of Biogen’s FDA-approved Alzheimer’s disease drug Aduhelm faced a lot of pushback in 2022, both from the market and from Congress, over what was viewed as a hasty fast-track approval process and exorbitant costs to patients.

Biogen gave it another go with Leqembi (lecanemab-irmb), its amyloid-beta monoclonal antibody for the treatment of Alzheimer’s disease, which the FDA approved in 2023 under its accelerated approval pathway. The drug was jointly developed by Biogen and Tokyo-based pharmaceutical company Eisai (OTC Pink:ESALF,TSE:4523). It is for patients with mild cognitive impairment or mild dementia, and is the first drug shown to slow the progression of Alzheimer’s disease to win FDA approval.

In January 2025, Leqembi received another FDA approval, this time for intravenous maintenance dosing for early-stage Alzheimer’s. Later, in April, the European Commission granted Leqembi Marketing Authorization in the EU for the treatment of mild early-stage Alzheimer’s disease.

That same month, the FDA granted fast track designation to Biogen’s investigational tau-targeting therapy BIIB080 for the treatment of Alzheimer’s.

Biogen’s earnings report for Q1 shows that first quarter global in-market sales of Leqembi reached approximately US$96 million, including US in-market sales of approximately US$52 million.

2. Acadia Pharmaceuticals (NASDAQ:ACAD)

Market cap: US$3.68 billion
Share price: US$21.98

Acadia Pharmaceuticals specializes in neuroscience and neuro-rare diseases. The biotech’s product portfolio includes the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, as well as the first and only approved drug in the United States and Canada for the treatment of Rett syndrome.

Acadia’s clinical-stage pipeline includes drug candidates targeting Prader-Willi syndrome and Alzheimer’s disease psychosis.

The company expects to enroll its final patient in its RADIANT Phase 2 study of ACP-204 in Alzheimer’s disease psychosis by early 2026 and release topline data in mid-2026.

According to the company, there are currently no approved treatments for hallucinations and delusions associated with Alzheimer’s disease psychosis.

3. Anavex Life Sciences (NASDAQ:AVXL)

Market cap: US$642.85 million
Share price: US$7.53

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative, neurodevelopmental and neuropsychiatric disorders, such as Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome and other central nervous system disorders.

Anavex’ lead drug candidate, Anavex 2-73 (blarcamesine), has successfully completed Phase 2a and a Phase 2b/3 clinical trials for Alzheimer’s disease.

In early January, the company announced positive topline safety and efficacy data from more than three years of continuous treatment with blarcamesine for early Alzheimer’s disease patients. Later that month, Anavex announced it had been issued a US patent for the treatment.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Challenger Gold Limited (ASX: CEL) (‘CEL’ or the ‘Company’) is pleased to announce it has entered into an Investment Protection Agreement (“IPA” or “the Agreement”) with the Government of Ecuador for its 100% owned El Guayabo Project (“El Guayabo” or “the Project”). Under the terms of the IPA, the Government of Ecuador has granted CEL legal protections including stability of the regulatory framework, resolution of disputes through international arbitration, and protection of CEL’s investment.

The IPA covers US$75 million in investment from CEL encompassing expenditures from CEL’s initial acquisition of the project in 2019 and expenditure incurred until the end of 2027. It has an initial term of 8 years and is renewable. Key incentives and protections under the IPA include:

  • Regulatory stability and protection from changes to the current legal framework
  • The legal framework at the time of execution will continue to apply if the terms are more favourable to the project owner than any potential new framework
  • The IPA guarantees rights including non-discriminatory treatment, property protection, and legal certainty
  • International arbitration, should there be any disputes in relation to the Project, with the seat of arbitration in London under the rules of the International Chamber of Commerce

Commenting on the Investment Protection Agreement, CEL Managing Director, Mr Kris Knauer, said

“The completion of the Investment Protection Agreement is a significant development for the Project..

The IPA provides certainty with respect to the legal framework governing the Project, including stable mining regulations and fiscal terms, and security of title and investment for the term of the agreement. Additionally, it provides protection from all forms of confiscation and a mechanism for international arbitration should there be any disputes related to the project.

The IPA is also timely given recent corporate action in Ecuador as we take steps to monetise our Ecuador assets following the significant resource upgrade from 4.5 million ounce1 to 9.1 million ounces1,2,3.

Click here for the full ASX Release

This post appeared first on investingnews.com

McLaren Minerals Limited (ASX: MML) (‘McLaren’ or ‘Company’), is pleased to provide a further update on the phase 1 Drill Program at its wholly owned McLaren Titanium Project in the western Eucla Basin, Western Australia. This update is driven by the completion of geological interpretation of all the drilling during this campaign, in the absence of laboratory results.

Highlights

McLaren Titanium Project

  • 192 drill holes completed for a total of 4,067 metres, on time and without incident
  • Significant extensions of prospective sediments outside of currently known resource boundaries observed during drilling:
    • North extension: approximately 2,200m wide, avg. 14m thick (max 23m),
    • Central zone eastern extension: 800m wide, avg. 20m thick (max 23m),
    • Southern zone: 2,600m wide, avg. 10m thick (max 15m).
  • Metallurgical and geological samples submitted to IHC and Diamantina Laboratories
  • Geological work has improved confidence in deposit morphology and is expected to reduce future drilling costs
  • Strong community support confirmed within an established mining region

McLaren Mineral Sands Managing Director, Simon Finnis, commented:

“While we have not yet received any assays, phase 1 has delivered strong confidence to our team regarding this project. The most recent interpretation not only confirm the integrity of our geological model, but importantly, demonstrates the scale of the opportunity ahead. Defining substantial potential for mineralisation outside the current Resource boundary positions us well for future resource growth. We’ve also made solid ground operationally—drilling was completed on time, we’ve brought costs down, and we’re seeing strong local support. Taken together, these outcomes give us a great deal of confidence as we move toward the next phase of work and continue building long-term value for shareholders.”

Click here for the full ASX Release

This post appeared first on investingnews.com

 western copper and gold corporation (‘Western’ or the ‘Company’) (TSX: WRN) (NYSE American: WRN) is pleased to announce that Mitsubishi Materials Corporation (‘Mitsubishi Materials’) has completed the precondition for the previously announced extension of their investor rights agreement.

Mitsubishi Materials acquired two million common shares of the Company through open market purchases, taking their overall ownership to approximately 5%. Consequently, the investor rights agreement between the two groups has now been extended to May 30, 2026 , in accordance with the amended terms announced on April 15, 2025 .

‘We are extremely pleased to maintain, and enhance, our relationship with Mitsubishi Materials.’ said Sandeep Singh , President and CEO. ‘They remain an incredibly supportive shareholder, and we value their expertise as we advance the Casino Project.’

ABOUT western copper and gold corporation

western copper and gold corporation is developing the Casino Project, Canada’s premier copper-gold mine in the Yukon Territory and one of the most economic greenfield copper-gold mining projects in the world.

The Company is committed to working collaboratively with our First Nations and local communities to progress the Casino Project, using internationally recognized responsible mining technologies and practices.

For more information, visit www.westerncopperandgold.com .

On behalf of the board,

‘Sandeep Singh’

Sandeep Singh
President and CEO
western copper and gold corporation

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain ‘forward-looking information’ and ‘forward-looking statements’ (collectively ‘forward-looking statements’) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date of this news release. Forward-looking statements are frequently, but not always, identified by words such as ‘expects’, ‘anticipates’, ‘believes’, ‘plans’, ‘projects’, ‘intends’, ‘estimates’, ‘envisages’, ‘potential’, ‘possible’, ‘strategy’, ‘goals’, ‘opportunities’, ‘objectives’, or variations thereof or stating that certain actions, events or results ‘may’, ‘could’, ‘would’, ‘might’ or ‘will’ be taken, occur or be achieved, or the negative of any of these terms and similar expressions. Such forward-looking statements herein include statements regarding the anticipated advancement of the Casino Project, the continued support and involvement of Mitsubishi Materials, and the potential benefits of the extended investor rights agreement.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual events to be materially different from those expressed or implied by such statements. Such factors include but are not limited to the risk of unforeseen challenges in advancing the Casino project, potential impacts on operational continuity, changes in general market conditions that could affect the Company’s performance; and other risks and uncertainties disclosed in the Company’s annual information form and Form 40-F for the most recently completed financial year and its other publicly filed disclosure documents.

Forward-looking statements are based on assumptions management believes to be reasonable, such assumptions and factors as set out herein, and in the Company’s annual information form and Form 40-F for the most recently completed financial year and its other publicly filed disclosure document.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, other factors may cause results to be materially different from those anticipated, described, estimated, assessed or intended. These forward-looking statements represent the Company’s views as of the date of this news release. There can be no assurance that any forward-looking statements will be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not intend to and does not assume any obligation to update forward-looking statements other than as required by applicable law.

View original content to download multimedia: https://www.prnewswire.com/news-releases/western-copper-formally-extends-investor-rights-agreement-with-mitsubishi-materials-302466858.html

SOURCE western copper and gold corporation

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/28/c7490.html

News Provided by Canada Newswire via QuoteMedia

This post appeared first on investingnews.com

Gov. Ron DeSantis urged House Republicans to take note of Florida’s successful implementation of ‘DOGE’-type governance and get moving on slashing waste, fraud and abuse identified by the executive branch organization.

‘Elon Musk took massive incoming – including attacks on his companies as well as personal smears, to lead the effort on DOGE,’ DeSantis posted on X.

‘He became public enemy #1 of legacy media around the world. To see Republicans in Congress cast aside any meaningful spending reductions (and, in fact, fully fund things like USAID) is demoralizing and represents a betrayal of the voters who elected them,’ the Republican said on Tuesday.

DeSantis had reposted a comment from former government scientist Matt van Swol, who claimed congressional Republicans have not done enough to go to bat for DOGE.

‘DOGE is literally one of the most popular government initiatives in history. 73% of Americans say they support cutting government waste. Trump brought in the smartest man on earth to do it… …the Left destroyed Elon for it …the GOP won’t vote on it I can’t believe this,’ van Swol said in the shared message.

In remarks Tuesday, DeSantis expounded upon his concerns, saying that Florida’s executive branch has successfully implemented DOGE-type policies in the state, increasing affordability, lowering taxes and ridding Tallahassee of waste and fraud.

He said Florida has been a state for 180 years, and it was his own administration who reportedly paid down 41% of its accumulated debt to-date. 

DeSantis said the average Floridian’s share of the state debt is $400, while federally, their onus is about $105,000.

The governor noted how Musk stuck his neck out for DOGE and saw his car dealerships ‘firebombed’ and how the media ‘smearing him relentlessly because he basically said, look, we can’t keep doing this…’

‘And yet, we have a Republican Congress, and to this day, we’re in the end of May, past Memorial Day, and not one cent in DOGE cuts have been implemented by the Congress,’ the one-time congressman said.

‘That’s one of the reasons why we need a balanced budget amendment to the U.S. Constitution. It’s another reason why we need term limits for members of Congress. But I think what you’ve seen with how, and I kind of said this early on, that DOGE and Elon were on a collision course with the swamp.’

Libertarian-minded Rep. Thomas Massie, R-Ky., had lodged a similar complaint – claiming that rescission votes to act on DOGE’s proposed cuts were ‘cancelled’ earlier in May – but a top aide to House Speaker Mike Johnson, R-La., disputed the claim. 

‘No votes on rescissions were cancelled this week. The Speaker has repeatedly expressed his commitment to save taxpayer funds via the rescissions process,’ wrote press secretary Athina Lawson.

‘Under law, this process requires a special message to Congress detailing proposed rescissions before Congress can act.’

House Republicans could not include any DOGE cuts in the ‘big beautiful bill’ because, in order to pass the Senate, the bill could only deal with statutorily ‘mandatory’ spending concerns.

The rules of Senate Reconciliation preclude that move as well.

The two options House Republicans have are to wait for a formal rescission request for a cut or cuts from Office of Management and Budget Director Russ Vought – a Trump appointee – and take that up within 45 days, or try to pass separate legislation themselves through the appropriations process.

The issue with the latter is that legislation independent of a request originating from the executive branch would require 60 votes – while a rescission request only requires a simple majority.

Republicans currently hold 53 seats in the Senate. Two independents – Sens. Bernie Sanders of Vermont and Angus King, Jr. of Maine – caucus with Democrats.

However, Republicans have had luck putting Democrats in a bind via the appropriations process, as the last passage of the typically massive bills led to members of that party turning on its leader – Sen. Charles Schumer of New York – for ultimately voting to fund the government earlier this year.

Fox News Digital reached out to DeSantis and Johnson for comment.

This post appeared first on FOX NEWS